Anti-Human CD279 (PD-1) (Nivolumab) - APC
Catalogue Number: 12-8038-ABO
| Manufacturer: | Abeomics |
| Type: | Recombinant Monoclonal |
| Alias: | PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 50 ug |
| Host name: | Human |
| Clone: | 5C4.B8 |
| Isotype: | |
| Immunogen: | Human PD-1 |
| Application: | FACS |
Description
Description: Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only. Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers. PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity. Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands. Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone. This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.
Additional Text
Antibody Clonality
Monoclonal
Application Notes
Endotoxin : <= 1.0 EU/mg as determined by the LAL method The suggested concentration for Nivolumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
12-8038 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations